FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileOrthocell Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
OCC.AX
Orthocell Limited Stock AnalysisComprehensive stock analysis for Orthocell Limited (OCC.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisOCC.AX
OCC.AX
Orthocell Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
OCC.AX
  1. Home
  2. Stocks
  3. Orthocell Limited

Orthocell Limited

🇦🇺OCC.AX•ASX

Orthocell Limited

🇦🇺OCC.AX•ASX

Your view on OCC.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Orthocell Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Paul Frederick Anderson
Headquarters
Building 191, Murdoch, WA, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Paul Frederick Anderson
Headquarters
Building 191, Murdoch, WA, AU
Description

Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries.

The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries.

Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle.

Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Orthocell Limited. Starting points for Orthocell Limited: EPS -AUD 0.05, beta -0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Orthocell Limited. Orthocell Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Orthocell Limited. Trailing twelve-month EPS for Orthocell Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrSep 2023Next QtrDec 2023Current YearFY Jun 2027Next YearFY Jun 2028
Avg. estimateAUD 0.00AUD 0.00−AUD 0.05−AUD 0.02
Low estimateAUD 0.00AUD 0.00−AUD 0.05−AUD 0.03
High estimateAUD 0.00AUD 0.00−AUD 0.04−AUD 0.02
No. of analysts0011
Year-ago EPS——−AUD 0.05—
Growth——+10.3%—

Revenue Estimate

RevenueCurrent QtrSep 2023Next QtrDec 2023Current YearFY Jun 2027Next YearFY Jun 2028
Avg. estimateAUD 4.25MAUD 4.25MAUD 15.95MAUD 30.65M
Low estimateAUD 4.25MAUD 4.25MAUD 15.00MAUD 24.10M
High estimateAUD 4.25MAUD 4.25MAUD 16.90MAUD 37.20M
No. of analysts1122
Year-ago revenue——AUD 11.41M—
Growth——+39.8%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Orthocell Limited. Orthocell Limited has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold OCC.AX18 companies
Compare OCC.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ARX.AXAroa Biosurgery LimitedHealthcareMedical - Devices—
CMB.AXCambium Bio LimitedHealthcareBiotechnology—
OSX.AXOsteopore LimitedHealthcareMedical - Instruments & Supplies—
PNV.AXPolyNovo LimitedHealthcareMedical - Devices—
TRP.AXTissue Repair LtdHealthcareBiotechnology—
TTX.AXTetratherix Ltd.HealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$869
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$373.3M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.8M
PCVXVaxcyte, Inc.HealthcareNASDAQ$9.3B
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Orthocell Limited. Coverage tracks Orthocell Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Orthocell Limited.

OCC.AX AnalysisFair
Past
1
Growth
5
Health
5
Profit
1
Value
1

News

Latest Market News